J&J releases encouraging data on Talvey combination therapies

Johnson & Johnson (NYSE:JNJ) said updated data from a Phase 1b study of Talvey in combination with Darzalex Faspro and pomalidomide showed an overall response rate of 82% in patients with relapsed or refractory multiple myeloma.

The updated results also showed a 100% overall response rate, with 56% of patients achieving complete response or better with weekly dosing. For bi-weekly dosing, the overall response rate was 76%, according to a statement.

The company also released encouraging data from a Phase 1b study of Talvey in combination with its BCMA-directed bispecific therapy Tecvayli in the treatment of relapsed or refractory multiple myeloma.

The data was presented at the annual meeting of the International Myeloma Society.

J&J’s (JNJ) Talvey, a bispecific T-cell engager targeting GPRC5D, is approved under the FDA’s accelerated approval pathway for the treatment of relapsed or refractory multiple myeloma patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Darzalex Faspro, an anti-CD38 monoclonal antibody also sold by J&J (JNJ), is approved for the treatment of patients with multiple myeloma.

Pomalidomide is marketed by Bristol Myers (BMY) under the brand name Pomalyst for relapsed multiple myeloma.